NEW YORK – LGC Clinical Diagnostics on Tuesday announced a partnership with AccuGenomics to jointly develop quality control materials for next-generation sequencing tests.
Financial terms of the codevelopment agreement were not disclosed.
The collaboration will make us of LGC's expertise in quality control and AccuGenomics' NGS monitoring technologies. The goal is to develop accurate and reliable molecular diagnostics and quality control materials for cancer NGS testing as well as custom reference materials for NGS assay validation.
"We are delighted to partner with AccuGenomics to further our mission of providing laboratories with cutting-edge quality control solutions," said Bharathi Anekella, executive VP of UK-based LGC Clinical Diagnostics, in a statement.
"This partnership with LGC will expand the reach of our proprietary technologies and enable more laboratories to improve the reliability of their patient testing by NGS," said Nick Lazaridis, president of Wilmington, North Carolina-based AccuGenomics. He added that he expects the collaboration to accelerate the adoption of his company's Accukit ctDNA MRD IS and Accukit Myeloid DNA IS products.